| Bioactivity | Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1]. |
| Invitro | Indatuximab ravtansine（1 pM-100 nM；5 天）在 RPMI 8226、MOLP-8 和 U266 细胞系（显着的 CD138 表达）中显示出细胞毒性作用，对 RPMI 8226、MOLP-8 的 IC50 值分别为 200 pM、40 pM 和 20 pM[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Indatuximab ravtansine 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | Indatuximab ravtansine（5.3-21.2 mg/kg；静脉注射；一次）在体内抑制多发性骨髓瘤肿瘤生长并提高宿主存活率[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1238517-16-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kurt Schönfeld, et al. Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies. J Hematol Oncol. 2017 Jan 11;10(1):13. |